Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study
Journal article published in 2023 by
Efstathios Kastritis 
,
Evangelos Terpos ,
Argiris Symeonidis ,
Vasiliki Labropoulou,
Sosana Delimpasi ,
Katia Mancuso,
Elena Zamagni,
Eirini Katodritou ,
Elena Rivolti,
Marie‐Christine Kyrtsonis,
Maria Roussou,
Despina Fotiou,
Foteini Theodorakakou,
Ioannis Ntanasis‐Stathopoulos ,
Evdoxia Hatjiharissi
and other authors.
,
Evangelos Terpos ,
Argiris Symeonidis ,
Vasiliki Labropoulou,
Sosana Delimpasi ,
Katia Mancuso,
Elena Zamagni,
Eirini Katodritou ,
Elena Rivolti,
Marie‐Christine Kyrtsonis,
Maria Roussou,
Despina Fotiou,
Foteini Theodorakakou,
Ioannis Ntanasis‐Stathopoulos ,
Evdoxia Hatjiharissi
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 